CLINICAL TRIALS PROFILE FOR DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
✉ Email this page to a colleague
All Clinical Trials for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03094052 ↗ | Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | Recruiting | Napo Pharmaceuticals, Inc. | Phase 2 | 2018-10-09 | This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer. |
| NCT03094052 ↗ | Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | Recruiting | Puma Biotechnology, Inc. | Phase 2 | 2018-10-09 | This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer. |
| NCT03094052 ↗ | Incidence and Severity of Diarrhea in Patients With Stage II-IIIC HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib | Recruiting | University of California, San Francisco | Phase 2 | 2018-10-09 | This phase II trial studies the incidence and severity of diarrhea in patients with stage II-IIIC HER2 Positive breast cancer treated with trastuzumab and neratinib. Trastuzumab is a form of targeted therapy because it attaches itself to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors. When trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the body's immune system. Neratinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving trastuzumab and neratinib may work better in treating patients with stage II-IIIC HER2 positive breast cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Condition Name
| Condition Name for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE | |
| Intervention | Trials |
| Stage IIA Breast Cancer AJCC v6 and v7 | 1 |
| Stage IIB Breast Cancer AJCC v6 and v7 | 1 |
| Stage III Breast Cancer AJCC v7 | 1 |
| Stage IIIA Breast Cancer AJCC v7 | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Trials by Country
Clinical Trial Progress for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Clinical Trial Phase
Clinical Trial Sponsors for DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE
Sponsor Name
